Who is Online

We have 57 guests and no members online

 

Biomass

 

Biomass is already widely exploited in Australia with over 30 generators (as large as 63MW) in Qld and five in NSW consuming sugarcane bagasse. Co-firing in thermal stations has also been applied on a limited basis. Installed biomass capacity has been surpassed by wind power because the present biomass resource is limited to agricultural by-product and hardwood woodchip.

 

In the Bayswater B Submissions Report - AECOM states:

 

The inclusion of biomass co-firing is an option for thermal plant. It increases the capital costs and degrades plant performance. Macquarie Generation has been active in the utilisation of biomass firing to replace coal. The quantity of saw mill residue and vegetable oil co-fired at Bayswater and Liddell was less than 1% by mass due to limited supplies of biomass and plant performance issues. Furthermore biomass had to be sourced from distances up to 300 km incurring prohibitive transport costs. An additional concern is the use of diesel fuel consumed with associated GHG emissions for the transport of the biomass.

 

Macquarie Generation does not currently fire biomass at Bayswater and Liddell due to the impact the low energy fuel has on plant output and the high cost of transport and handling which makes it uneconomic. The lack of available locally sourced biomass and its high cost make biomass co-firing presently non-viable. It is also understood that the future availability of sawmill waste is threatened as a result of the declining native timber hardwood industry.

 

The specific energies of softwoods are significantly lower resulting in little if any useful heat release.

 

A related, emerging technology, might be called bio-solar. This employs genetically modified algae or other biological organisms to absorb solar energy to convert CO2to hydrocarbons for fuel (or plastic and other organic chemistry manufacture). This technology has potential to reduce electricity demand by displacing electricity in a number of industrial and transport processes.

 

 

 

 

No comments

Travel

Cruising to PNG

 

 

 

 

On the 17th February 2020 Wendy and I set sail on Queen Elizabeth on a two week cruise up to Papua New Guinea, returning to Sydney on 2nd March. 

Read more: Cruising to PNG

Fiction, Recollections & News

The new James Bond

 

 

It was raining in the mountains on Easter Saturday.

We'd decided to take a couple of days break in the Blue Mountains and do some walking. But on Saturday it poured.  In the morning we walked two kilometres from Katoomba to more up-market and trendy Leura for morning coffee and got very wet.

After a train journey to Mount Victoria and back to dry out and then lunch in the Irish Pub, with a Cider and Guinness, we decided against another soaking and explored the Katoomba antique stores and bookshops instead.  In one I found and bought an unread James Bond book.  But not by the real Ian Fleming. 

Ian Fleming died in 1964 at the young age of fifty-six and I'd read all his so I knew 'Devil May Care' was new.  This one is by Sebastian Faulks, known for his novel Birdsong, 'writing as Ian Fleming' in 2008.

Read more: The new James Bond

Opinions and Philosophy

The race for a SARS-CoV-2 vaccine

 

 

 

 

As we all now know (unless we've been living under a rock) the only way of defeating a pandemic is to achieve 'herd immunity' for the community at large; while strictly quarantining the most vulnerable.

Herd immunity can be achieved by most people in a community catching a virus and suffering the consequences or by vaccination.

It's over two centuries since Edward Jenner used cowpox to 'vaccinate' (from 'vacca' - Latin for cow) against smallpox. Since then medical science has been developing ways to pre-warn our immune systems of potentially harmful viruses using 'vaccines'.

In the last fifty years herd immunity has successfully been achieved against many viruses using vaccination and the race is on to achieve the same against SARS-CoV-2 (Covid-19).

Developing; manufacturing; and distributing a vaccine is at the leading edge of our scientific capabilities and knowledge and is a highly skilled; technologically advanced; and expensive undertaking. Yet the rewards are potentially great, when the economic and societal consequences of the current pandemic are dire and governments around the world are desperate for a solution. 

So elite researchers on every continent have joined the race with 51 vaccines now in clinical trials on humans and at least 75 in preclinical trials on animals.

Read more: The race for a SARS-CoV-2 vaccine

Terms of Use

Terms of Use                                                                    Copyright